Etemad-Moghadam B, Rhone D, Steenbeke T, Sun Y, Manola J, Gelman R, Fanton J W, Racz P, Tenner-Racz K, Axthelm M K, Letvin N L, Sodroski J
Department of Cancer Immunology and AIDS, Dana-Farber Cancer institute, Harvard Medical School, Boston, Massachusetts 02115, USA.
J Virol. 2001 Jun;75(12):5646-55. doi: 10.1128/JVI.75.12.5646-5655.2001.
The mechanism of the progressive loss of CD4+ T lymphocytes, which underlies the development of AIDS in human immunodeficiency virus (HIV-1)-infected individuals, is unknown. Animal models, such as the infection of Old World monkeys by simian-human immunodeficiency virus (SHIV) chimerae, can assist studies of HIV-1 pathogenesis. Serial in vivo passage of the nonpathogenic SHIV-89.6 generated a virus, SHIV-89.6P, that causes rapid depletion of CD4+ T lymphocytes and AIDS-like illness in monkeys. SHIV-KB9, a molecularly cloned virus derived from SHIV-89.6P, also caused CD4+ T-cell decline and AIDS in inoculated monkeys. It has been demonstrated that changes in the envelope glycoproteins of SHIV-89.6 and SHIV-KB9 determine the degree of CD4+ T-cell loss that accompanies a given level of virus replication in the host animals (G. B. Karlsson et. al., J. Exp. Med. 188:1159-1171, 1998). The envelope glycoproteins of the pathogenic SHIV mediated membrane fusion more efficiently than those of the parental, nonpathogenic virus. Here we show that the minimal envelope glycoprotein region that specifies this increase in membrane-fusing capacity is sufficient to convert SHIV-89.6 into a virus that causes profound CD4+ T-lymphocyte depletion in monkeys. We also studied two single amino acid changes that decrease the membrane-fusing ability of the SHIV-KB9 envelope glycoproteins by different mechanisms. Each of these changes attenuated the CD4+ T-cell destruction that accompanied a given level of virus replication in SHIV-infected monkeys. Thus, the ability of the HIV-1 envelope glycoproteins to fuse membranes, which has been implicated in the induction of viral cytopathic effects in vitro, contributes to the capacity of the pathogenic SHIV to deplete CD4+ T lymphocytes in vivo.
CD4+ T淋巴细胞进行性丧失的机制尚不清楚,而这一机制是人类免疫缺陷病毒(HIV-1)感染个体发生艾滋病的基础。动物模型,如用猿猴-人类免疫缺陷病毒(SHIV)嵌合体感染旧世界猴,有助于研究HIV-1的发病机制。非致病性SHIV-89.6在体内连续传代产生了一种病毒SHIV-89.6P,该病毒可导致猴体内CD4+ T淋巴细胞迅速耗竭及类似艾滋病的疾病。SHIV-KB9是一种从SHIV-89.6P衍生而来的分子克隆病毒,也可导致接种猴体内CD4+ T细胞减少和发生艾滋病。已证明,SHIV-89.6和SHIV-KB9包膜糖蛋白的变化决定了在宿主动物中伴随一定水平病毒复制的CD4+ T细胞丧失程度(G.B.卡尔森等人,《实验医学杂志》188:1159 - 1171, 1998)。致病性SHIV的包膜糖蛋白介导膜融合的效率高于其亲本非致病性病毒。在此我们表明,决定这种膜融合能力增加的最小包膜糖蛋白区域足以将SHIV-89.6转化为一种可导致猴体内CD4+ T淋巴细胞严重耗竭的病毒。我们还研究了两个单氨基酸变化,它们通过不同机制降低了SHIV-KB9包膜糖蛋白的膜融合能力。这些变化中的每一个都减弱了在SHIV感染猴中伴随一定水平病毒复制的CD4+ T细胞破坏。因此,HIV-1包膜糖蛋白融合膜的能力(这在体外病毒细胞病变效应的诱导中起作用)有助于致病性SHIV在体内耗竭CD4+ T淋巴细胞的能力。